Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [SCLC Tuba-seq]

ABSTRACT: A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [SCLC Tuba-seq]

PROVIDER: PRJNA816202 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer

Project description:RNA-seq, LCM sequencing, and Tuba-seq data for the article titled, "A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer." This SuperSeries is composed of the SubSeries listed below.

2023-01-09 | GSE198637 | GEO

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [SCLC Tuba-seq]

Project description:We generated a model of lentivirus-initiated mouse small cell lung cancer (SCLC) combined with CRISPR/Cas9 knockout and barcoding. We analyzed tumor suppressive functions of 39 gene candidates using these in vivo CRISPR screening approaches and found Tsc1 to be one of the top tumor suppressor genes in SCLC.

2023-01-09 | GSE198636 | GEO

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [LCM Tuba-seq]

Project description:A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [LCM Tuba-seq]

| PRJNA816203 | ENA

In vivo multiplexed screen reveals a critical role of Keap1/Nrf2 pathway in small cell lung cancer [TUBAseq]

Project description:Approximately 15% of all lung cancer cases are small cell lung cancer (SCLC), which originates from neuroendocrine cells lining the airways (bronchi) of the lung. SCLC is known for its aggressive nature and swift growth, resulting in a five-year survival rate of around 6%. Understanding the genetic pathways that drive tumor development remains an ongoing challenge. In our study, we employed an in vivo multiplexed approach, known as Tuba-seq, to investigate the impact of the functional loss of 18 putative tumor suppressors. Our screening unveiled Pten and Keap1 as top candidates; knocking out either one promoted both tumor initiation and progression. We identified the Keap1/Cul3/Nrf2 pathway as a pivotal regulator for SCLC development, particularly in regulating the susceptibility of SCLC to ferroptosis. Our work not only established an in vivo multiplexed approach for assessing the role of tumor suppressors in SCLC but also uncovers a previously unappreciated role of Keap1 in SCLC.

2024-01-26 | GSE239440 | GEO

In vivo multiplexed screen reveals a critical role of Keap1/Nrf2 pathway in small cell lung cancer [RNAseq]

2024-01-26 | GSE239436 | GEO

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [LCM Tuba-seq]

2023-01-09 | GSE198635 | GEO

A PKA/PP2A AXIS DRIVES THE GROWTH OF NEUROENDOCRINE SCLC

Project description:Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer whose biology is still poorly understood. Using a multiplexed inhibitor beads assay, we identified active kinases in SCLC. Among those, we found that PKA is critical for the expansion of SCLC in culture and in vivo. PKA promotes the neuroendocrine epithelial state associated with SCLC tumor-initiating cells. Phosphoproteomics analyses identify ~200 PKA substrates and show that PKA controls multiple facets of SCLC growth. Notably, the PP2A phosphatase counteracts the oncogenic effects of PKA, and PP2A activators inhibit SCLC as single agents and with chemotherapy. Our data uncover key signaling networks in SCLC and indicate that targeting the PKA/PP2A pathway may help inhibit this lethal neuroendocrine cancer.

2020-02-11 | GSE126353 | GEO

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer

Project description:A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer

| PRJNA816196 | ENA

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [RNAseq]

2023-01-09 | GSE198634 | GEO

Microenvironment Shapes Small Cell Lung Cancer Neuroendocrine States and Presents Therapeutic Opportunities [DMS273 SCLC cell lines]

Project description:Small-cell lung cancer (SCLC) is the most fatal form of lung cancer. Intra-tumoral heterogeneity, marked by neuroendocrine (NE) and non-neuroendocrine (non-NE) cell states, defines SCLC, but the drivers of SCLC plasticity are poorly understood. To map the landscape of SCLC tumor microenvironment (TME), we apply spatially resolved transcriptomics and quantitative mass spectrometry-based proteomics to metastatic SCLC tumors obtained via rapid autopsy. The phenotype and overall composition of non-malignant cells in the tumor microenvironment (TME) exhibits substantial variability, closely mirroring the tumor phenotype, suggesting TME-driven reprogramming of NE cell states. We identify cancer-associated fibroblasts (CAF) as a crucial element of SCLC TME heterogeneity, contributing to immune exclusion, and predicting exceptionally poor prognosis. Together, our work provides a comprehensive map of SCLC tumor and TME ecosystems, emphasizing their pivotal role in SCLCs adaptable nature, opening possibilities for re-programming the intercellular communications that shape SCLC tumor states.

2024-05-16 | GSE267560 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data